Journal: Oncology Letters
Article Title: The cytotoxicity of gefitinib on patient‑derived induced pluripotent stem cells reflects gefitinib‑induced liver injury in the clinical setting
doi: 10.3892/ol.2023.14108
Figure Lengend Snippet: EGFR expression, and the phosphorylation following gefitinib treatment in the clones of patient-derived iPSCs or iPSC-heps from the N or T group. Western blot analyses of (A) iPSCs and (B) iPSC-heps from the N or T group. EGFR expression was detected with an anti-EGFR antibody. Densitometric analysis was performed using ImageJ software for (C) iPSCs and (D) iPSC-heps. (E) iPSCs were cultured with gefitinib at indicated concentrations (0, 3, 6 µM) for two days. The cell lysates were subjected to western blot analysis. EGFR and pEGFR expressions were detected with their respective antibodies (Upper panel). GAPDH was used as a loading control. (F) Densitometric analysis (n=3) was performed using ImageJ software (Lower panel). The values represented mean ± SD. *P<0.05, Dunnett's test. T, toxicity; N, no toxicity; EGFR, epidermal growth factor receptor; pEGFR, phosphorylated EGFR; iPSCs, induced pluripotent stem cells; iPSC-heps, iPSC-hepatocytes.
Article Snippet: Anti-EGFR antibodies (sheep polyclonal, Upstate ® , Merck, Darmstadt, DE), phospho-EGFR (Y1068) [mouse monoclonal (m), Abcam, Cambridge, UK], GAPDH (m, MBL, Nagoya, Japan), human albumin (goat polyclonal, Bethyl Laboratories, Montgomery, TX), α-fetoprotein [rabbit monoclonal (r, mAb), Abcam, Cambridge, UK], and hepatocyte nuclear factor 4 alpha (HNF4α) (r, mAb, Abcam, Cambridge, UK) were used for our experiments.
Techniques: Expressing, Phospho-proteomics, Clone Assay, Derivative Assay, Western Blot, Software, Cell Culture, Control